TISIDB

Summary
Symbol	TRIP13
Name	thyroid hormone receptor interactor 13
Aliases	16E1BP; thyroid receptor interacting protein 13; 16E1-BP; HPV16 E1 protein binding protein; HPV16 E1 protein ......
Chromosomal Location	5p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	-
Domain	PF00004 ATPase family associated with various cellular activities (AAA)
Function	Plays a key role in chromosome recombination and chromosome structure development during meiosis. Required at early steps in meiotic recombination that leads to non-crossovers pathways. Also needed for efficient completion of homologous synapsis by influencing crossover distribution along the chromosomes affecting both crossovers and non-crossovers pathways. Also required for development of higher-order chromosome structures and is needed for synaptonemal-complex formation. In males, required for efficient synapsis of the sex chromosomes and for sex body formation. Promotes early steps of the DNA double-strand breaks (DSBs) repair process upstream of the assembly of RAD51 complexes. Required for depletion of HORMAD1 and HORMAD2 from synapsed chromosomes (By similarity). Plays a role in mitotic spindle assembly checkpoint (SAC) activation (PubMed:28553959).

> Gene Ontology [ TOP ]
Biological Process	GO:0001556 oocyte maturation GO:0006302 double-strand break repair GO:0006310 DNA recombination GO:0007059 chromosome segregation GO:0007126 meiotic nuclear division GO:0007127 meiosis I GO:0007129 synapsis GO:0007130 synaptonemal complex assembly GO:0007131 reciprocal meiotic recombination GO:0007140 male meiosis GO:0007141 male meiosis I GO:0007143 female meiotic division GO:0007144 female meiosis I GO:0007281 germ cell development GO:0007283 spermatogenesis GO:0007286 spermatid development GO:0007292 female gamete generation GO:0009994 oocyte differentiation GO:0021700 developmental maturation GO:0022412 cellular process involved in reproduction in multicellular organism GO:0035825 reciprocal DNA recombination GO:0045132 meiotic chromosome segregation GO:0045143 homologous chromosome segregation GO:0048232 male gamete generation GO:0048469 cell maturation GO:0048477 oogenesis GO:0048515 spermatid differentiation GO:0048599 oocyte development GO:0051321 meiotic cell cycle GO:0070192 chromosome organization involved in meiotic cell cycle GO:0070193 synaptonemal complex organization GO:0098813 nuclear chromosome segregation GO:1903046 meiotic cell cycle process
Molecular Function	-
Cellular Component	GO:0001673 male germ cell nucleus GO:0043073 germ cell nucleus

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	TRIP13
Name	thyroid hormone receptor interactor 13
Aliases	16E1BP; thyroid receptor interacting protein 13; 16E1-BP; HPV16 E1 protein binding protein; HPV16 E1 protein ......
Chromosomal Location	5p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between TRIP13 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	TRIP13
Name	thyroid hormone receptor interactor 13
Aliases	16E1BP; thyroid receptor interacting protein 13; 16E1-BP; HPV16 E1 protein binding protein; HPV16 E1 protein ......
Chromosomal Location	5p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of TRIP13 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -2.40; FDR: 0.04630	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	TRIP13
Name	thyroid hormone receptor interactor 13
Aliases	16E1BP; thyroid receptor interacting protein 13; 16E1-BP; HPV16 E1 protein binding protein; HPV16 E1 protein ......
Chromosomal Location	5p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of TRIP13 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.604	0.0899
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.196	0.891
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.908	0.433
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.119	0.825
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.051	0.971
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.208	0.901
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.074	0.849
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.591	0.648
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.683	0.57
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.523	0.427
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.035	0.968
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.468	0.0025

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of TRIP13 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	0	7.4	0.0709
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	0	7.4	0.096
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	TRIP13
Name	thyroid hormone receptor interactor 13
Aliases	16E1BP; thyroid receptor interacting protein 13; 16E1-BP; HPV16 E1 protein binding protein; HPV16 E1 protein ......
Chromosomal Location	5p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TRIP13. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	TRIP13
Name	thyroid hormone receptor interactor 13
Aliases	16E1BP; thyroid receptor interacting protein 13; 16E1-BP; HPV16 E1 protein binding protein; HPV16 E1 protein ......
Chromosomal Location	5p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TRIP13. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TRIP13. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	TRIP13
Name	thyroid hormone receptor interactor 13
Aliases	16E1BP; thyroid receptor interacting protein 13; 16E1-BP; HPV16 E1 protein binding protein; HPV16 E1 protein ......
Chromosomal Location	5p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TRIP13. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	TRIP13
Name	thyroid hormone receptor interactor 13
Aliases	16E1BP; thyroid receptor interacting protein 13; 16E1-BP; HPV16 E1 protein binding protein; HPV16 E1 protein ......
Chromosomal Location	5p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of TRIP13 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	TRIP13
Name	thyroid hormone receptor interactor 13
Aliases	16E1BP; thyroid receptor interacting protein 13; 16E1-BP; HPV16 E1 protein binding protein; HPV16 E1 protein ......
Chromosomal Location	5p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between TRIP13 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	TRIP13
Name	thyroid hormone receptor interactor 13
Aliases	16E1BP; thyroid receptor interacting protein 13; 16E1-BP; HPV16 E1 protein binding protein; HPV16 E1 protein ......
Chromosomal Location	5p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting TRIP13 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse TRIP13